ML
ALNY icon

McAdam LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

McAdam LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-400
Closed -$35K – 79
2018
Q3 		$35K Sell
400
-5
-1% -$503 0.01% 193
2018
Q2 		$40K Buy
405
+5
+1% +$496 0.02% 174
2018
Q1 		$48K Buy
+400
New +$51.6K 0.02% 157

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

McAdam LLC's ALNY Position: Q4 2018 in Review

McAdam LLC sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2018, closing a stake of 400 shares — an estimated $35K sold.

McAdam LLC first reported a position in ALNY in Q1 2018 and held it in 3 quarters. The position peaked at $48K in Q1 2018. 284 funds tracked by Wall St. Rank hold ALNY as of Q4 2018.

  • McAdam LLC reported no remaining Alnylam Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • McAdam LLC sold 400 Alnylam Pharmaceuticals shares in Q4 2018, an estimated $35K.
  • McAdam LLC first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • McAdam LLC's Alnylam Pharmaceuticals position peaked at $48K in Q1 2018.
  • 284 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.